Trial Profile
Dual Therapy Combining Raltegravir With Etravirine Maintains a High Level of Viral Suppression Over 96 Weeks in Long-term Experienced HIV-infected Individuals Over 45 Years on a PI-based Regimen: Results From the Phase II ANRS 163 ETRAL Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Etravirine (Primary) ; Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms ETRAL
- 07 Aug 2020 Results published in the AIDS
- 07 Apr 2020 Results (n=19) assessing virological rebounds (plasma viral load >50 copies/mL), published in the Journal of Antimicrobial Chemotherapy.
- 03 Jul 2019 Results published in the Journal of Antimicrobial Chemotherapy